The Romanian pharmaceutical market reached 14.1 billion lei (EUR3 billion) sales in 2017, up 9% on the previous year, market research company Cegedim data show. Sales of drugs doubled compared 2008, ZF has found from Cegedim data.
“We are expecting a RON1 billion to RON2 billion market growth in 2019-2020 as a result of new molecules being introduced in the conditional and non-conditional subsidy systems. In the absence of proportionate funding, the amounts due for the growth will be paid by manufacturers via the clawback tax, to which generic drug manufacturers, which do not benefit from revenue, will contribute, as well,” Dragos Damian, CEO of pharmaceutical manufacturer Terapia in Cluj-Napoca, told ZF.
The subsidized and free drugs offered to Romanian patients in 2018 will be paid for by the National Health Insurance House budget, via the national health insurance fund, about RON6 billion, from the clawback tax paid by producers, RON3 billion, and patient co-pay, about RON1 billion, Dragos Damian says.
The top 20 actors on the Romanian pharmaceutical market posted almost RON9.5 billion sales in 2017, accounting for 67% of the total market, ZF has calculated from Cegedim data.
Market leader is AbbVie for the third year in a row, having posted RON1.4 billion sales and climbing to the top spot because of the sales of a subsidized viral hepatitis drug.
Second leading manufacturer is Sanofi, RON972 million sales in 2017, followed by Novartis, RON630 million.
(English version by Loredana Fratila-Cristescu)